A nanodiamond is forever. At least, in terms of fluorescent signal, they are. Fluorescent nanodiamonds never photobleach or blink. They are tiny fluorescent sources of steady and permanent near infrared light that can be leveraged to detect targets deep in tissue.
Bikanta’s nanodiamonds are superior optical probes for:
✓ Brightness & Signal Stability
✓ Biocompatibility (no toxicity)
✓ Customizability (to target specific diseases)
Bikanta is also designing novel imaging scanners and microscopes to improve detection capabilities. Nanodiamonds are exquisitely sensitive to magnetic fields. This sensitivity can be used to reduce background noise more than 100-fold over current methods and to improve visualization deeper into the body. Already, Bikanta’s technology has been used to visualize lymph nodes that were invisible in conventional imaging, the first step to early metastatic node detection.
Nanodiamonds truly are our best friends.
Bikanta’s founder Ambika Bumb graduated from Georgia Tech and obtained her doctorate from Oxford while on the prestigious Marshall Scholarship. She completed two post-doctoral fellowships at the National Cancer Institute and National Heart, Lung and Blood Institute where she developed Bikanta’s nanodiamond-based technologies. She has received numerous scholarships and awards for excellence in engineering and was profiled in 2011 in Nature as a successful young scientist on the fast-track. Her endeavors in the areas of nanomedicine and diagnostics have led to multiple patents and many publications.
A serial inventor with 8 patents, Oxford alumni Terry Sachlos previously co-founded TEOX Ltd which developed customizable bone grafts. As CSO of TEOX, Terry was instrumental in winning the Oxford University Business Competition and raising first-round funding for TEOX. He continued with postdocs at MIT, Harvard and McMaster University. His findings have led to a clinical trial to repurpose thioridazine as an agent able to selectively target cancer stem cells present in acute myeloid leukemia (AML) patients.
Bikanta’s Board of Advisors is being led by Professor Peter Dobson, Principal Fellow at University of Warwick’s Manufacturing Group. As Director of Oxford’s Begbroke Science Park from 2002-2013, he was involved in the initial stages of many (>25) start-up companies. He has himself spun-off multiple companies including Oxonica, Oxford Biosensors, and Oxford NanoSystems, published over 180 papers and 30 patents, and been the Strategic Advisor on Nanotechnology to the UK Research Councils.
Harvard MBA and finance executive Ileane Rosenthal, has been the Co-Founder of the International Biomedical Research Alliance, President of Churchill Partners, and Executive Vice President of Securities Industry and Financial Markets Association (SIMFA). She brings strengths in strategic business development, client relationship management, marketing, funding, and program growth.
Bikanta’s work has been published on the covers of leading journals and as featured spotlights:
In the Press